Rhenman & Partners Asset Management AB Increases Stock Position in Nuvalent, Inc. $NUVL

Rhenman & Partners Asset Management AB lifted its holdings in shares of Nuvalent, Inc. (NASDAQ:NUVL) by 211.1% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 163,350 shares of the company’s stock after acquiring an additional 110,850 shares during the quarter. Nuvalent accounts for about 1.5% of Rhenman & Partners Asset Management AB’s investment portfolio, making the stock its 25th largest holding. Rhenman & Partners Asset Management AB’s holdings in Nuvalent were worth $16,431,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in shares of Nuvalent by 13.9% during the 4th quarter. Vanguard Group Inc. now owns 5,244,271 shares of the company’s stock valued at $527,521,000 after buying an additional 639,264 shares in the last quarter. Wellington Management Group LLP lifted its stake in shares of Nuvalent by 46.0% during the 3rd quarter. Wellington Management Group LLP now owns 2,300,865 shares of the company’s stock valued at $198,979,000 after buying an additional 724,491 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Nuvalent by 32.9% during the 4th quarter. JPMorgan Chase & Co. now owns 2,205,251 shares of the company’s stock valued at $221,826,000 after buying an additional 545,542 shares in the last quarter. State Street Corp lifted its stake in shares of Nuvalent by 4.2% during the 2nd quarter. State Street Corp now owns 1,490,279 shares of the company’s stock valued at $113,708,000 after buying an additional 59,620 shares in the last quarter. Finally, Commodore Capital LP lifted its stake in shares of Nuvalent by 1.8% during the 3rd quarter. Commodore Capital LP now owns 1,400,000 shares of the company’s stock valued at $121,072,000 after buying an additional 25,000 shares in the last quarter. 97.26% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Nuvalent

Here are the key news stories impacting Nuvalent this week:

• Positive Sentiment: GSK’s purchase underscores strong strategic demand for Nuvalent’s oncology assets, especially its selective tyrosine kinase inhibitor programs, which supports the view that the company’s pipeline has major pharma value. Reuters article on GSK deal
• Positive Sentiment: Market commentary and analyst coverage suggest the acquisition is strategically important for GSK’s oncology rebuild, reinforcing confidence that the transaction is meaningful and likely to close. Reuters article on GSK oncology rebuild
• Neutral Sentiment: Several analyst downgrades followed the takeover announcement, but their revised price targets remain close to the deal price, so the impact on the stock appears limited. Analyst downgrade coverage
• Neutral Sentiment: Law firms have begun reviewing whether the sale process and price were fair, which could create headline noise but does not change the announced terms. Business Wire article on investigation
• Negative Sentiment: CEO James Richard Porter sold 30,000 shares, which may slightly weigh on sentiment by suggesting insiders have been reducing exposure ahead of the transaction. SEC insider filing

Analyst Upgrades and Downgrades

Several analysts have issued reports on NUVL shares. HC Wainwright cut shares of Nuvalent from a “buy” rating to a “neutral” rating and set a $124.00 target price on the stock. in a research note on Tuesday. TD Cowen cut shares of Nuvalent from a “buy” rating to a “hold” rating and set a $124.00 target price on the stock. in a research note on Tuesday. Wells Fargo & Company reiterated an “equal weight” rating and issued a $124.00 target price (up from $116.00) on shares of Nuvalent in a research note on Tuesday. Robert W. Baird set a $122.85 target price on shares of Nuvalent in a research note on Tuesday. Finally, Raymond James Financial cut shares of Nuvalent from an “outperform” rating to a “market perform” rating in a research note on Tuesday. Five analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Nuvalent currently has a consensus rating of “Hold” and an average price target of $131.15.

Insider Activity at Nuvalent

In other news, insider Henry E. Pelish sold 3,093 shares of the stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $104.48, for a total value of $323,156.64. Following the transaction, the insider owned 65,604 shares of the company’s stock, valued at $6,854,305.92. This represents a 4.50% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Deborah Ann Miller sold 5,500 shares of the stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $107.84, for a total transaction of $593,120.00. Following the completion of the transaction, the insider directly owned 59,634 shares in the company, valued at $6,430,930.56. The trade was a 8.44% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 126,953 shares of company stock worth $12,612,264 over the last quarter. 5.02% of the stock is currently owned by corporate insiders.

Nuvalent Price Performance

NASDAQ NUVL opened at $123.25 on Friday. Nuvalent, Inc. has a 1 year low of $71.13 and a 1 year high of $123.62. The stock has a market capitalization of $9.74 billion, a PE ratio of -20.34 and a beta of 1.15. The company’s 50 day simple moving average is $104.21 and its two-hundred day simple moving average is $103.45.

Nuvalent (NASDAQ:NUVL) last posted its earnings results on Thursday, May 7th. The company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.35) by ($0.04). During the same period last year, the firm posted ($1.18) EPS. On average, research analysts anticipate that Nuvalent, Inc. will post -5.74 EPS for the current year.

Nuvalent Profile

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.